$2.08
-0.22-9.57%
Last update: Nov 10, 1:39 PM
Kalaris Therapeutics Inc
KLRSNASDAQ
Kalaris Therapeutics fell 52.1% from $4.80 to $2.30, behind the S&P 500's +10.5%. Its worst day was Dec 19 (−12.4%), and its low came Oct 26 at $1.80.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.64 missed the $-0.63 estimate on $0.00 revenue.
−2.2% · S&P 500 +0.1%
Kalaris Therapeutics shares rose 15.6%, while the S&P 500 fell 0.1%.
Story events cover the past 12 months · Times ET
+15.6% · S&P 500 −0.1%
Kalaris Therapeutics shares rose 20.3%, while the S&P 500 fell 1.1%.
+20.3% · S&P 500 −1.1%
Kalaris Therapeutics shares rose 18.4%, while the S&P 500 rose 0.7%.
+18.4% · S&P 500 +0.7%
Kalaris Therapeutics closed at its highest level of the year, 128.8% above where the year started.
+7.2% · S&P 500 −0.3%
EPS of $-0.44 beat the $-0.55 estimate on $0.00 revenue.
−3.3% · S&P 500 +0.3%
EPS of $-0.46 beat the $-0.52 estimate on $0.00 revenue.
+1.3% · S&P 500 −0.2%
Kalaris Therapeutics shares rose 15.4%, while the S&P 500 rose 1.4%.
+15.4% · S&P 500 +1.4%
EPS of $-0.48 beat the $-0.50 estimate on $0.00 revenue.
+0.8% · S&P 500 −0.3%
Kalaris Therapeutics closed at its lowest level of the year, 62.5% below where the year started.
−3.7% · S&P 500 +0.7%
Where it ended: a close of $2.30 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.52).
Nothing in the past 12 months.
All KLRS dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KLRS and SPY from Benzinga historical bars. Not investment advice.
